![Luiz Belardinelli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luiz Belardinelli
Technik-/Wissenschafts-/F&E-Leiter bei InCarda Therapeutics, Inc.
Aktive Positionen von Luiz Belardinelli
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Technik-/Wissenschafts-/F&E-Leiter | 05.04.2016 | - |
Karriereverlauf von Luiz Belardinelli
Ehemalige bekannte Positionen von Luiz Belardinelli
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Corporate Officer/Principal | - | 02.05.2011 |
Statistik
International
Vereinigte Staaten | 3 |
Operativ
Corporate Officer/Principal | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Sektoral
Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |
- Börse
- Insiders
- Luiz Belardinelli
- Erfahrung